On the evening of February 3, 2023, Structure Therapeutics will be officially listed on the NASDAQ market in the United States. The IPO intends to raise US$160 million and plans to issue 120.74 million American Depositary Shares (ADSs) at an issue price of US$15.00 per ADS.
Structure Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of novel oral small molecule therapies for metabolic and pulmonary diseases. To date, Structure Therapeutics has designed a differentiated therapeutic product pipeline to overcome the limitations of biologics and peptide therapies targeting GPCR cell surface families, and the therapeutic field targets chronic diseases with unmet medical needs.
The listing was co-underwriters by Jefferies, SVB Leerink, Guggenheim Securities and BMO Capital Markets.
Cooley LLP and Zhong Lun Law Firm are the company's U.S. legal counsel and China's legal counsel, respectively.
Latham & Watkins LLP acted as legal counsel to the underwriters.